EFHD1 Protein Linked to Progression of Fatty Liver Disease

EFHD1 Identified as Driver of Liver Injury

Researchers at the University of Utah have identified the protein EFHD1 as a key factor that drives the progression from fatty liver to liver injury. Their findings suggest that EFHD1 triggers an antiviral immune response in the liver, which leads to inflammation and scarring.

The study, published in the Journal of Clinical Investigation, found that EFHD1 acts differently from most genes previously linked to metabolic liver disease, which typically affect fat metabolism. Instead, EFHD1 appears to influence whether a fatty liver becomes damaged, regardless of fat levels.

Study Evidence: Human Cells and Mouse Models

The research team used both human liver organoids and mouse models to test the effects of EFHD1. Mice genetically engineered to lack EFHD1 showed changes in their liver mitochondria and were less likely to develop liver injury when exposed to a high-fat, high-sugar diet.

Blocking or reducing EFHD1 in these models led to a 30% to 60% reduction in inflammation and liver scarring. This effect was seen in both diet-induced and drug-induced liver injury models, as well as in human cells.

How EFHD1 Causes Liver Damage

EFHD1 helps mitochondria divide by tethering them to the endoplasmic reticulum. In the presence of high fat, EFHD1 levels rise, causing mitochondria to divide excessively and leak their contents.

This leakage includes double-stranded RNA, which the liver cell mistakes for a viral infection. The resulting antiviral response shuts down healthy liver cells, increasing injury and scarring.

Implications for Metabolic Health Management

Current drugs for metabolic liver disease mostly target fat metabolism and often only partially resolve liver injury. EFHD1 represents a new target that could be used alongside existing therapies.

By blocking EFHD1, it may be possible to reduce liver injury and give people more time to make lifestyle changes that address underlying metabolic issues.

Limitations and Next Steps

The findings are based on preclinical studies in mice and human liver organoids. More research is needed to determine if EFHD1 inhibition is safe and effective in people with fatty liver disease.

The study does not address whether EFHD1 affects the accumulation of fat in the liver, only the progression to injury and scarring.